New developments in the FDA Approval of essential thrombocythemia (ET) are attracting attention across the myeloproliferative neoplasm (MPN) community. Among the most discussed developments is the clinical evidence surrounding ropeginterferon alfa-2b and its evaluation in the phase 3 SURPASS-ET study. SURPASS-ET examined ropeginterferon alfa-2b against anagrelide in adults with essential thrombocythemia who had previously received …
SURPASS-ET Explained: Ropeginterferon Alfa-2b, Anagrelide, and the Future of ET Care

